Mounjaro (Tirzepatide) NICE approved Mounjaro for weight loss in June 2024, marking a significant milestone in weight loss treatments
For injectable semaglutide (Ozempic, Wegovy) and other GLP-1 receptor agonists, taste disturbances are not specifically highlighted among the most common adverse effects, though gastrointestinal symptoms that might indirectly affect taste perception are well-documented
Currently, the core registration studies to assess the efficacy of retatrutide include: TRIUMPH-1 : A randomized, double-blind, placebo-controlled trial to test the safety and effectiveness of a treatment for people with obesity or overweight, including those with OSA and OA, but without type 2 diabetes
The Three Nutritional Pillars That Drive Retatrutide Results Before diving into specific foods and meal timing, three principles form the backbone of every successful Retatrutide eating plan